title: GCF and serum myeloperoxidase and matrix metalloproteinase-13 levels in renal transplant patients.
abstract: OBJECTIVE
  The rationale of this study was to address whether local or systemic changes reflect proteolytic (matrix metalloproteinase-13) or oxidative (myeloperoxidase) stress in renal transplant patients receiving cyclosporine-A (CsA) and having gingival overgrowth (GO), in patients receiving CsA therapy and having no GO and patients receiving tacrolimus therapy.
  
  
  METHODS
  Gingival crevicular fluid (GCF) samples were collected from sites with (GO+) and without GO (GO-) in CsA patients having GO; GO- sites in CsA patients having no GO; sites from tacrolimus, gingivitis and healthy subjects. GCF and serum myeloperoxidase (MPO) and matrix metalloproteinase-13 (MMP-13) levels were determined by ELISA.
  
  
  RESULTS
  GO+ sites in CsA patients having GO had elevated GCF MPO levels than those of CsA patients having no GO, tacrolimus and healthy subjects (p<0.005), but comparable to those of gingivitis. GCF MPO levels were higher in GO+ compared to GO- sites in CsA patients having GO (p<0.05). Patient groups had similar, but higher GCF MMP-13 levels than healthy group.
  
  
  CONCLUSIONS
  These results show that CsA and tacrolimus therapy have not a significant effect on GCF MPO and MMP-13 levels, and gingival inflammation seems to be the main reason for their elevations.
authors.affiliation: Ege University, School of Dentistry, Department of Periodontology, Bornova, 35100 Izmir, Turkey. gemingil@yahoo.com
authors.forename: Gülnur
authors.initials: G
authors.lastname: Emingil
authors.forename: Beral
authors.initials: B
authors.lastname: Afacan
authors.forename: Taina
authors.initials: T
authors.lastname: Tervahartiala
authors.forename: Hüseyin
authors.initials: H
authors.lastname: Töz
authors.forename: Gül
authors.initials: G
authors.lastname: Atilla
authors.forename: Timo
authors.initials: T
authors.lastname: Sorsa
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D016572:Cyclosporine / Q000009:adverse effects* / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005883:Gingival Crevicular Fluid / Q000201:enzymology*; D019214:Gingival Overgrowth / Q000097:blood / Q000139:chemically induced* / Q000201:enzymology; D005891:Gingivitis / Q000201:enzymology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000097:blood; D016030:Kidney Transplantation; D008297:Male; D053509:Matrix Metalloproteinase 13 / Q000032:analysis / Q000097:blood / Q000378:metabolism*; D008875:Middle Aged; D016011:Normal Distribution; D009195:Peroxidase / Q000032:analysis / Q000097:blood / Q000378:metabolism*; D018709:Statistics, Nonparametric; D016559:Tacrolimus / Q000097:blood / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D009195:Peroxidase; D053509:Matrix Metalloproteinase 13; D016559:Tacrolimus